Selective Serotonin Reuptake Inhibitor Add-On Therapy for the Negative Symptoms of Schizophrenia

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: I read with interest the recent meta-analysis by Sepehry et al.1 of selective serotonin reuptake inhibitor (SSRI) add-on therapy for negative symptoms of schizophrenia and am concerned that their negative conclusion largely reflects methodological limitations. The small number and heterogeneity of available studies make meta-analytic analyses at this time particularly vulnerable to confounds.2 Further, optimal use was not made of available studies: all participants in our original study3 received typical antipsychotics (the only ones available then), a fact easily clarified, and thus were eligible for subanalyses of that group.​

J Clin Psychiatry 2008;69(1):163-164